The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the advantages of CAR T-cells derived from pluripotent stem cells?

During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Maria Themeli, Amsterdam UMC, Amsterdam, NL. We asked, What are the advantages of CAR T-cells derived from pluripotent stem cells?

What are the advantages of CAR T-cells derived from pluripotent stem cells?

In this video, the background to the use of induced pluripotent stem cells (iPCs) is discussed along with the role of genome editing with respect to the production of these CAR T-cells.

Share: